

Docket Number: PU60756

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Lee, et al.	3 July 2008
Appln. No.:	10/589,995	Group Art Unit: 1625
Filed:	August 18, 2006	Examiner: Patricia L. Morris
For:	PYRIDONE	

RESPONSE TO RESTRICTION REQUIREMENT

In response to the Examiner's Restriction Requirement from the Office Action dated June 23, 2008, Applicants select Group I (Claims 1-3). Additionally, Applicants elect 4-(4-fluorophenyl)-*N*-1*H*-indazol-5-yl-2-methyl-6-oxo-1,4,5,6-tetrahydro-3 pyridinecarboxamide, (See Example 2, page 25). Applicants further elect glaucoma as the specific disease to be treated.

Authorization is hereby granted to charge any fees which may be required by this paper to Deposit Account No. 19-2570.

Respectfully submitted,



Reid S. Willis

Agent for Applicants

Registration No. 39,429

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-7481
Fax (610) 270-5090